Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL
The U.S. Food and Drug Administration (FDA) has approved the cell therapy Aucatzyl (obecabtagene autoleucel) to treat adults with relapsed or refractory precursor B-cell acute…
New CAR T-cell Therapy Seen to Induce Lasting Remission in Advanced Multiple Myeloma Patients
An ongoing Phase 1 trial testing a novel CAR T-cell therapy has shown promising results in relapsed or treatment-resistant (refractory) multiple myeloma patients. The new anti-BCMA…
Immunotherapy Helps Myeloma Patients Who Relapse After Stem Cell Transplant, Study Shows
Many patients with blood cancers, such as myeloma, go into remission after receiving a stem-cell transplant. However, there are still many patients (about one-third) who relapse, a condition…
